UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study

International journal of clinical practice (Esher), 2011-09, Vol.65 (9), p.945-953

2011

Volltextzugriff (PDF)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1163-1171

2008

Volltextzugriff (PDF)

Review of the usual treatment of adults with type 2 diabetes in Japan

Value in health, 2014-05, Vol.17 (3), p.A262-A262

2014

Volltextzugriff (PDF)

The heterogeneity of antipsychotic response in the treatment of schizophrenia

Psychological medicine, 2011-06, Vol.41 (6), p.1291-1300

2011

Volltextzugriff (PDF)

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy

ClinicoEconomics and outcomes research, 2013-01, Vol.5 (default), p.407-418

2013

Volltextzugriff (PDF)

Cost Implications Of Early Discontinuation And Restart Of Insulin In The Treatment Of Type 2 Diabetes Mellitus

Value in health, 2014-05, Vol.17 (3), p.A264-A264

2014

Volltextzugriff (PDF)

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

The journal of clinical psychiatry, 2006-03, Vol.67 (3), p.453-460

2006

Volltextzugriff (PDF)

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being

Pharmacopsychiatry, 2013-05, Vol.46 (3), p.114-119

2013

Volltextzugriff (PDF)

Increased Burden On Primary Care Physicians Preceding Diagnosis Of Alzheimer's Disease In The United Kingdom

Value in health, 2013-05, Vol.16 (3), p.A201-A201

2013

Volltextzugriff (PDF)

PMH5 Does Participation in a Weight Control Program Also Improve Clinical and Functional Outcomes for Chinese Patients with Schizophrenia Treated with Olanzapine?

Value in health, 2012-11, Vol.15 (7), p.A669-A669

2012

Volltextzugriff (PDF)

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

European psychiatry, 2011-07, Vol.26 (5), p.313-319

2011

Volltextzugriff (PDF)

PMH5 Empirically-Driven Definitions of “Good” “Moderate” and “Poor” Levels of Functioning in the Treatment of Schizophrenia

Value in health, 2011, Vol.14 (7), p.A287-A287

2011

Volltextzugriff (PDF)

PMH4 Extent of Attaining and Maintaining Symptom Remission by Antipsychotic Medication in the Treatment of Chronic Schizophrenia: Evidence from the Catie Study

Value in health, 2011, Vol.14 (7), p.A287-A287

2011

Volltextzugriff (PDF)

PMH3 Olanzapine Long-Acting Injection for Schizophrenia: An Evaluation of Patient Functioning During 24 Weeks of Maintenance Therapy

Value in health, 2011, Vol.14 (7), p.A287-A287

2011

Volltextzugriff (PDF)

PMH12 Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine

Value in health, 2011, Vol.14 (7), p.A288-A289

2011

Volltextzugriff (PDF)

PMH13 Differences Between Patients Undergoing Augmentation or Switching of Antipsychotic Medications During Treatment of Schizophrenia

Value in health, 2011, Vol.14 (7), p.A289-A289

2011

Volltextzugriff (PDF)

P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study

European neuropsychopharmacology, 2010, Vol.20, p.S464-S464

2010

Volltextzugriff (PDF)

The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs

Pharmacopsychiatry, 2010-05, Vol.43 (3), p.81-85

2010

Volltextzugriff (PDF)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone

Schizophrenia bulletin, 2007-11, Vol.33 (6), p.1379-1387

2007

Volltextzugriff (PDF)

42 – Number needed to treat (NNT) for all-cause medication discontinuation from randomized controlled trials comparing olanzapine to other antipsychotics for the treatment of schizophrenia

Schizophrenia research, 2008-02, Vol.98, p.50-51

2008

Volltextzugriff (PDF)

41 – Early onset of antipsychotic action in schizophrenia: A clinical marker discriminating active drug from placebo

Schizophrenia research, 2008-02, Vol.98, p.50-50

2008

Volltextzugriff (PDF)

S.05.02 Early response as a response predictor: use of individual variability in clinical trials

European neuropsychopharmacology, 2009, Vol.19, p.S183-S183

2009

Volltextzugriff (PDF)

P.3.c.060 Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia

European neuropsychopharmacology, 2008, Vol.18, p.S438-S439

2008

Volltextzugriff (PDF)

P.3.c.040 Antipsychotic effectiveness based on early response in the treatment of schizophrenia

European neuropsychopharmacology, 2007, Vol.17, p.S447-S448

2007

Volltextzugriff (PDF)

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

Journal of clinical psychopharmacology, 2006-04, Vol.26 (2), p.157-162

2006

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(136)

Sprache

Englisch
(136)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Internal Medicine
(45)
Psychiatry
(41)
Schizophrenia
(40)
Humans
(34)
Adult
(25)
Female
(25)
Schizophrenia - Drug Therapy
(25)
Antipsychotic Agents - Therapeutic Use
(22)
Male
(22)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Psychology. Psychoanalysis. Psychiatry
(20)
Psychopathology. Psychiatry
(18)
Antipsychotics
(17)
Olanzapine
(17)
Middle Aged
(16)
Adult And Adolescent Clinical Studies
(15)
Treatment Outcome
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Review of the usual treatment of adults with type 2 diabetes in Japan

The heterogeneity of antipsychotic response in the treatment of schizophrenia

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy

Cost Implications Of Early Discontinuation And Restart Of Insulin In The Treatment Of Type 2 Diabetes Mellitus

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being

Increased Burden On Primary Care Physicians Preceding Diagnosis Of Alzheimer's Disease In The United Kingdom

PMH5 Does Participation in a Weight Control Program Also Improve Clinical and Functional Outcomes for Chinese Patients with Schizophrenia Treated with Olanzapine?

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

PMH5 Empirically-Driven Definitions of “Good” “Moderate” and “Poor” Levels of Functioning in the Treatment of Schizophrenia

PMH4 Extent of Attaining and Maintaining Symptom Remission by Antipsychotic Medication in the Treatment of Chronic Schizophrenia: Evidence from the Catie Study

PMH3 Olanzapine Long-Acting Injection for Schizophrenia: An Evaluation of Patient Functioning During 24 Weeks of Maintenance Therapy

PMH12 Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine

PMH13 Differences Between Patients Undergoing Augmentation or Switching of Antipsychotic Medications During Treatment of Schizophrenia

P.3.c.011 Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study

The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone

42 – Number needed to treat (NNT) for all-cause medication discontinuation from randomized controlled trials comparing olanzapine to other antipsychotics for the treatment of schizophrenia

41 – Early onset of antipsychotic action in schizophrenia: A clinical marker discriminating active drug from placebo

S.05.02 Early response as a response predictor: use of individual variability in clinical trials

P.3.c.060 Differences in early responders/early non-responders to atypical antipsychotics on functional outcomes in schizophrenia

P.3.c.040 Antipsychotic effectiveness based on early response in the treatment of schizophrenia

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

Suchergebnisse filtern